110822-05-4

Basic information

• Product Name: (2-Bromomethyl)-4-methyl-1-nitrobenzene
• Synonyms: (2-Bromomethyl)-4-methyl-1-nitrobenzene
• CAS NO: 110822-05-4
• Molecular Formula: C₈H₈BrNO₂
• Molecular Weight: 230.06
• Mol File: 110822-05-4.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 303.97°C at 760 mmHg
• Flash Point: 137.637°C
• Appearance: /
• Density: 1.565g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.6
• CAS DataBase Reference: (2-Bromomethyl)-4-methyl-1-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: (2-Bromomethyl)-4-methyl-1-nitrobenzene(110822-05-4)
• EPA Substance Registry System: (2-Bromomethyl)-4-methyl-1-nitrobenzene(110822-05-4)

Safety Data

• Hazardous Substances Data: 110822-05-4(Hazardous Substances Data)

Usage

General Description

"(2-Bromomethyl)-4-methyl-1-nitrobenzene" is a chemical compound with a molecular formula of C8H8BrNO2. This organic compound is characterised by a benzene ring which carries a nitro group (-NO2) and a bromomethyl group (-CH2Br), making it an aromatic nitro compound and a bromoalkane. Its chemical structure includes a bromine atom, a nitro functional group, a methyl group, and a benzene ring. Although specific properties such as boiling point, melting point or solubility can vary based on conditions, it is typically known for its potential reactivity due to the presence of the nitro and bromine functionalities. Details of its reactivity, toxicity, or uses may not be readily available as this chemical is not commonly found or used, indicating it may be primarily used for specialized scientific or industrial purposes.

InChI:InChI=1/C8H8BrNO2/c1-6-2-3-8(10(11)12)7(4-6)5-9/h2-4H,5H2,1H3

Upstream product

• 3113-72-2 5-methyl-2-nitrobenzoic acid 
• 66424-92-8 5-methyl-2-nitrobenzyl alcohol 

Downstream Products

• 110822-07-6 N-(5-methyl-2-nitrobenzyl)thiazolidine-4-carboxylic acid 
• 85062-30-2 (4-Methoxy-benzyl)-(5-methyl-2-nitro-benzyl)-amine; hydrochloride 
• 1422192-97-9 4-methyl-2-((1-(phenylsulfonyl)piperidin-3-ylidene)methyl)aniline 
• 1009631-75-7 9-methyl-2-(phenylsulfonyl)-1,2,3,4,5,6-hexahydroazepino[4,3-b]indole 
• 1431090-02-6 3-(2-azido-5-methoxybenzylidene)-1-Boc-piperidine 
• 90765-19-8 2-(2-amino-5-methylphenyl)acetonitrile 

Relevant articles and documents

Synthesis of Aryl-Substituted 3,3a,4,5-Tetrahydropyrrolo[1,2- A [ quinolin-1(2 H)-ones and 2,3,4,4a,5,6-Hexahydro-1 H-pyrido[1,2- A [quinolin-1-ones

A new route to the title benzo-fused angular tricyclic amides 3,3a,4,5-tetrahydropyrrolo- A nd 2,3,4,4a,5,6-hexahydro-1 H-pyrido[1,2- A [quinolin-1-ones is reported from 1-(tert-butyl) 6-ethyl 3-oxohexanedioate and 1-(tert-butyl) 7-ethyl 3-oxoheptanedioate. Alkylation of these β-keto diesters with a series of 2-nitrobenzyl bromides followed by acid hydrolysis and decarboxylation gives ethyl 6-(2-nitrophenyl)-4-oxohexanoates and ethyl 7-(2-nitrophenyl)-5-oxoheptanoates, respectively. Reductive amination under hydrogenation conditions followed by ester hydrolysis and condensative ring closure affords the final lactam products. The reactions proceed cleanly and only two chromatographic purifications are required.

PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of Formula (I) and (II): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating H1 and 5-HT2A receptors and are to be used in the treatment of sleep disorders, such as sleep fragmentation, disturbed sleep/arousals, and arousal threshold.

JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE

Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): [FORMULA SHOULD BE INSERTED HERE] including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.